ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Stock analysts at B. Riley issued their Q3 2025 earnings per share (EPS) estimates for shares of ArriVent BioPharma in a research report issued to clients and investors on Monday, August 25th. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.80) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma's Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($4.30) EPS, FY2026 earnings at ($4.02) EPS, FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at $1.04 EPS.
A number of other equities research analysts also recently weighed in on the stock. Guggenheim reiterated a "buy" rating and issued a $45.00 price target on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. Wall Street Zen cut ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. The Goldman Sachs Group raised ArriVent BioPharma to a "buy" rating and set a $33.00 target price on the stock in a report on Thursday, July 10th. Zacks Research raised ArriVent BioPharma from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Finally, Jones Trading assumed coverage on shares of ArriVent BioPharma in a research report on Tuesday, May 20th. They set a "buy" rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $39.14.
Check Out Our Latest Stock Report on AVBP
ArriVent BioPharma Stock Down 1.9%
Shares of ArriVent BioPharma stock opened at $19.21 on Thursday. The stock has a market capitalization of $779.35 million, a price-to-earnings ratio of -4.78 and a beta of 1.17. ArriVent BioPharma has a twelve month low of $15.47 and a twelve month high of $36.37. The company has a 50-day simple moving average of $20.65 and a two-hundred day simple moving average of $21.06.
ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.20).
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of AVBP. Woodline Partners LP lifted its holdings in shares of ArriVent BioPharma by 0.4% in the first quarter. Woodline Partners LP now owns 146,373 shares of the company's stock worth $2,706,000 after acquiring an additional 576 shares during the last quarter. BNP Paribas Financial Markets increased its position in ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company's stock worth $56,000 after purchasing an additional 609 shares in the last quarter. MetLife Investment Management LLC lifted its stake in ArriVent BioPharma by 6.8% in the 4th quarter. MetLife Investment Management LLC now owns 17,460 shares of the company's stock valued at $465,000 after purchasing an additional 1,110 shares during the last quarter. Legal & General Group Plc lifted its stake in ArriVent BioPharma by 8.8% in the 2nd quarter. Legal & General Group Plc now owns 14,790 shares of the company's stock valued at $322,000 after purchasing an additional 1,197 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ArriVent BioPharma by 8.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,114 shares of the company's stock valued at $456,000 after buying an additional 1,327 shares in the last quarter. Institutional investors own 9.48% of the company's stock.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
